Cantor Fitzgerald, L. P. Seres Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $2.48 Billion
- Q4 2024
A detailed history of Cantor Fitzgerald, L. P. transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 95,740 shares of MCRB stock, worth $67,975. This represents 0.0% of its overall portfolio holdings.
Number of Shares
95,740
Previous 280,565
65.88%
Holding current value
$67,975
Previous $266,000
70.3%
% of portfolio
0.0%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding MCRB
# of Institutions
75Shares Held
41.3MCall Options Held
2.96MPut Options Held
228K-
Flagship Pioneering Inc. Cambridge, MA23.1MShares$16.4 Million5.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.87MShares$4.17 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.01MShares$1.43 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.81MShares$1.29 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.76MShares$1.25 Million0.0% of portfolio
About Seres Therapeutics, Inc.
- Ticker MCRB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,072,000
- Market Cap $88.1M
- Description
- Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...